Compare CAAS & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAS | NTHI |
|---|---|---|
| Founded | N/A | 2008 |
| Country | China | United States |
| Employees | 4812 | 5 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.7M | 139.1M |
| IPO Year | 2025 | N/A |
| Metric | CAAS | NTHI |
|---|---|---|
| Price | $4.67 | $4.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 31.3K | ★ 42.8K |
| Earning Date | 04-22-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.87 | $3.20 |
| 52 Week High | $5.15 | $12.99 |
| Indicator | CAAS | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 59.42 | 43.89 |
| Support Level | $4.12 | $4.17 |
| Resistance Level | $4.75 | $5.90 |
| Average True Range (ATR) | 0.14 | 0.48 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 81.58 | 37.01 |
China Automotive Systems Inc is a holding company. The firm, through its subsidiary, is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series of power steering models, including rack and pinion power steering, integral power steering, electronic power steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.